Company
Guerbet
Guerbet has 20 drugs tracked on RxWires: 13 post-market, 3 in Phase 2, 4 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Dotarem®-enhanced MRI | Post-Market | Renal Insufficiency |
| MRI | Post-Market | Pathological Processes |
| Gadoterate meglumine | Post-Market | Hepatocellular Carcinoma |
| Motor Tests | Post-Market | Motor Function |
| Iobitridol | Post-Market | Diagnostic Imaging |
| Dotarem | Post-Market | Peripheral Arterial Disease |
| Lipiodol Ultra Fluid with surgical glues | Post-Market | Congenital Hemangioma |
| Gadopiclenol | Post-Market | Prostate Cancer |
| Elucirem (Gadopiclenol) | Post-Market | Myocardial Fibrosis |
| Ioversol 320 mgI/mL | Post-Market | Renal Impairment |
| Gadolinium | Post-Market | Meniere's Disease |
| Iohexol | Post-Market | Hypothyroidism |
| Xenetix | Post-Market | Diagnostic Imaging |
| P03277 | Phase 2 | CNS Lesion |
| Idarubicin and Lipiodol | Phase 2 | Carcinoma, Hepatocellular |
| P03277 at 0.1 mmol/kg | Phase 2 | Chronic Liver Disease |
| Dotarem® IV injection at 0.1 mmol/kg | Phase 1 | End-stage Renal Failure |
| Iodixanol | Phase 1 | Malignant Neoplasm in the Head and Neck |
| P03277 0.1 mmol/kg | Phase 1 | Healthy Volunteers |
| Lipiodol | Phase 1 | Knee Osteoarthritis |
Latest
No recent events.
Follow Guerbet on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.